
    
      This is a randomized double-blind, control device clinical study across 5 sites, evaluating
      changes in terminal hair count in the evaluation zone having evidence of androgenetic
      alopecia (miniaturized hair).

      The trial with 60 female subjects who have been diagnosed with androgenetic alopecia, who are
      between 25 and 60 years of age, have Fitzpatrick Skin Types I-IV, with classifications of
      Ludwig I-4, II-1, II-2, or frontal, have active hair loss within the last 12 months.

      Subjects will use the device on three non-concurring days a week as directed per device for
      26 weeks duration.

      Initial efficacy endpoint for each subject will be assess at visit 4 (week 16).

      Safety analysis will be assessed based on the reports of adverse events during study.
    
  